New data on RevMed’s Rasonque leave potential opening for other treatments
Patients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’s shares {$RVMD} down more than 6% ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.